€102.40
0.29% yesterday
Paris, Dec 30, 05:35 pm CET
ISIN
FR0013280286
Symbol
BIM
Sector

bioMerieux SA Target price 2024 - Analyst rating & recommendation

bioMerieux SA Classifications & Recommendation:

Buy
81%
Hold
13%
Sell
6%

bioMerieux SA Price Target

Target Price €119.70
Price €102.40
Potential
Number of Estimates 16
16 Analysts have issued a price target bioMerieux SA 2025 . The average bioMerieux SA target price is €119.70. This is higher than the current stock price. The highest price target is
€130.00 26.95%
register free of charge
, the lowest is .
A rating was issued by 16 analysts: 13 Analysts recommend bioMerieux SA to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the bioMerieux SA stock has an average upside potential 2025 of . Most analysts recommend the bioMerieux SA stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Billion € 3.67 3.95
2.38% 7.40%
EBITDA Margin 21.64% 22.97%
4.99% 6.16%
Net Margin 9.72% 11.87%
22.93% 22.07%

15 Analysts have issued a sales forecast bioMerieux SA 2024 . The average bioMerieux SA sales estimate is

€3.9b
Unlock
. This is
3.69% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€4.0b 5.23%
Unlock
, the lowest is
€3.9b 2.01%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 €3.7b 2.38%
2024
€3.9b 7.40%
Unlock
2025
€4.2b 7.37%
Unlock
2026
€4.6b 7.74%
Unlock
2027
€5.0b 9.16%
Unlock
2028
€5.4b 7.87%
Unlock

14 Analysts have issued an bioMerieux SA EBITDA forecast 2024. The average bioMerieux SA EBITDA estimate is

€906m
Unlock
. This is
9.76% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€1.1b 31.70%
Unlock
, the lowest is
€833m 0.89%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 €795m 2.73%
2024
€906m 14.00%
Unlock
2025
€1.0b 11.36%
Unlock
2026
€1.1b 12.75%
Unlock
2027
€1.3b 13.62%
Unlock
2028
€1.4b 11.51%
Unlock

EBITDA Margin

2023 21.64% 4.99%
2024
22.97% 6.16%
Unlock
2025
23.82% 3.70%
Unlock
2026
24.93% 4.66%
Unlock
2027
25.94% 4.05%
Unlock
2028
26.82% 3.39%
Unlock

11 bioMerieux SA Analysts have issued a net profit forecast 2024. The average bioMerieux SA net profit estimate is

€469m
Unlock
. This is
14.16% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€494m 20.44%
Unlock
, the lowest is
€439m 6.98%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 €357m 21.09%
2024
€469m 31.12%
Unlock
2025
€526m 12.27%
Unlock
2026
€596m 13.27%
Unlock
2027
€695m 16.57%
Unlock
2028
€794m 14.30%
Unlock

Net Margin

2023 9.72% 22.93%
2024
11.87% 22.07%
Unlock
2025
12.41% 4.55%
Unlock
2026
13.05% 5.16%
Unlock
2027
13.93% 6.74%
Unlock
2028
14.76% 5.96%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share 3.03 3.97
21.09% 31.02%
P/E 25.70
EV/Sales 3.13

11 Analysts have issued a bioMerieux SA forecast for earnings per share. The average bioMerieux SA <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

€3.97
Unlock
. This is
14.08% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
€4.19 20.40%
Unlock
, the lowest is
€3.72 6.90%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 €3.03 21.09%
2024
€3.97 31.02%
Unlock
2025
€4.46 12.34%
Unlock
2026
€5.05 13.23%
Unlock
2027
€5.89 16.63%
Unlock
2028
€6.73 14.26%
Unlock

P/E ratio

Current 29.30 5.06%
2024
25.70 12.29%
Unlock
2025
22.89 10.93%
Unlock
2026
20.21 11.71%
Unlock
2027
17.34 14.20%
Unlock
2028
15.17 12.51%
Unlock

Based on analysts' sales estimates for 2024, the bioMerieux SA stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.24 0.31%
2024
3.13 3.51%
Unlock
2025
2.91 6.86%
Unlock
2026
2.70 7.19%
Unlock
2027
2.48 8.40%
Unlock
2028
2.29 7.30%
Unlock

P/S ratio

Current 3.16 1.87%
2024
3.05 3.56%
Unlock
2025
2.84 6.86%
Unlock
2026
2.64 7.19%
Unlock
2027
2.42 8.40%
Unlock
2028
2.24 7.30%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today